Infliximab, an anti-TNF agent, has been shown to reverse muscle volume and strength in patients with Crohn’s disease; however, an anti-TNF intervention did not block muscle atrophy in an arthritis animal model [36,37]. The gene discussed is TNF; the disease is Crohn disease.